The clot thickens (or not)

Blood

Volumn 114, Issue 9, 2009, Pages 1722-1723

  McKenzie, Steven E ^a   Reilly, Michael P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BOSUTINIB; DASATINIB; FC RECEPTOR IIA; IMATINIB; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RISTOCETIN; STEM CELL FACTOR;

BLEEDING; BLOOD CLOTTING; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG POTENCY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MUCOSAL BLEEDING; NONHUMAN; NOTE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA;

EID: 70449559119     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-226720     Document Type: Note

References (8)

1. Gratacap M-P, Martin V, Valéra M-C, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009;114(9):1884-1892.
2. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114(2): 261-263.
3. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27(3):469-471.
4. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110(12):4055-4063. (Pubitemid 350248462)
5. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25(9): 1035-1044. (Pubitemid 47517638)
6. Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer. 2009; 115(7):1381-1394.
7. Delaney S, Sinha U, Nanda N, et al. Specific pharmacological targeting of the Syk kinase activity in platelets: a novel, safe antithrombotic strategy [abstract]. Blood. 2008; 112(suppl):157. Abstract 409.
8. Reilly MP, Sinha U, Andre P, et al. PRT060318, a novel syk inhibitor, prevents heparin-induced thrombocytopenia in a transgenicmousemodel[abstract]. Blood. 2008;112(suppl): 106. Abstract 269.